Precision medicine’s blind spot: Rebalancing the evidence base to reflect women’s health Authors: Chloe E. Bird, Hamad Al Ibrahim Published: 2026 ABSTRACT Precision medicine requires an evidence base that reflects women’s biology, demanding reforms in funding, study design, and sex-disaggregated reporting. Precision medicine has transformed how we think about disease risk and treatment response. However, the field still rests on an evidence base that often treats the male body as the default. For decades, researchers favored male participants, in part to avoid the perceived “complexity” of hormonal cycles; female animals were excluded from basic studies, and women were sidelined in early-stage trials (1, 2). This legacy is not just a historical curiosity. It continues to shape what questions get asked, which data are collected, how results are interpreted, and who ultimately benefits from supposedly individualized care. The roots of this imbalance are well documented. In 1977, the US Food and Drug Administration advised excluding women of childbearing potential from early-phase drug trials after the thalidomide tragedy, a policy that effectively removed most premenopausal women from research for over a decade (2). Although the 1993 National Institutes of Health (NIH) Revitalization Act mandated the inclusion of women in NIH-funded clinical research, enrollment alone did not guarantee that outcomes were analyzed by sex. A decisive shift began two decades later: In 2014, NIH announced its Sex as a Biological Variable (SABV) policy to ensure that preclinical studies balance male and female cells and animals and that sex is considered as a variable in design and analysis (3). These policy milestones matter, but they have not yet fully corrected the evidence imbalance. Funding patterns underscore the shortfall. A synthesis aligned with a National Academies of Sciences, Engineering, and Medicine evaluation reported that only about 8.8% of NIH research funding from 2013 to 2023 focused on women’s health (4). That proportion is misaligned with women’s share of disease burden across the life course. The underinvestment constrains downstream activities, from the size and representativeness of study cohorts to the granularity of sex-disaggregated analyses and the development of diagnostics, therapeutics, and care pathways that work for women. Clinical trial participation tells a similar story. An analysis of 1433 US phase 1 to 3 trials between 2016 and 2019 found that, on average, only 41.2% of participants were female (5). Underrepresentation was most notable where disease burden among women is high: In cardiovascular trials, women comprised roughly 41.9% of participants despite representing about half of patients with cardiovascular disease; in cancer trials, women’s participation averaged ~41% although women account for about 51% of patients; and in psychiatry, trial enrollment among women averaged ~42% although women comprise roughly 60% of the patient population (5). Underpowered or absent sex-specific analyses then compound the problem, obscuring treatment effects in women and blunting signals that should guide clinical practice. These research gaps translate into clinical consequences. In a national cohort of more than 600,000 myocardial infarction cases in England and Wales, women were more likely than men to receive an incorrect initial diagnosis, a delay associated with worse outcomes (6). The result is not only missed opportunities for timely reperfusion and secondary prevention but also the embedding of bias into algorithms and heuristics that govern emergency care. Autoimmune diseases provide a second lens on the same problem: Roughly 80% of autoimmune patients are women (7), yet many report long delays before diagnosis and frequent psychosomatic mislabeling along the way, a pattern documented in mixed-methods research with patients living with lupus and related autoimmune conditions (8). When symptoms are dismissed or reframed as anxiety or depression, pathophysiology goes untreated, and trust erodes. The cumulative burden of these gaps emerges clearly in population health metrics. A 2024 analysis from the Global Burden of Disease Study reported consistent sex differences across the leading causes of disability-adjusted life years, with women bearing a greater share of nonfatal, chronic conditions, musculoskeletal disorders, migraine and other headaches, and depressive and anxiety disorders, which undermine quality of life (9). Women live longer than men in most countries, but they also spend a larger fraction of those years with illness and disability. An evidence base tuned to male phenotypes can miss how these conditions present in women, how they progress, and how they respond to treatment, resulting in a lack of evidence-based prevention and treatment to address these conditions in women and girls. Maternal health, intrinsically tied to women’s biology, lays bare the stakes of inattention. A 2024 NIH Pathways to Prevention panel synthesis published in a leading obstetrics journal concluded that the United States remains an outlier among high-income countries, with the highest maternal mortality rates and stark inequities by race and ethnicity (10). The panel emphasized that more than half of maternal deaths occur after delivery, in the postpartum period, precisely when continuity of care is fragile and coverage gaps are common (10). When a wealthy country cannot ensure safe pregnancy and postpartum care, it is a symptom of structural failure, not an inevitable byproduct of demographics. What does it mean to build precision medicine on evidence that actually fits women? First, it means recognizing sex as a fundamental source of biological variation, not a nuisance factor to be averaged away. Second, it means aligning funding and incentives with this reality: ensuring that diseases that uniquely or predominantly affect women, such as endometriosis, polyendocrine metabolic ovarian syndrome, and autoimmune disorders, receive sustained investment and that common conditions such as cardiovascular disease, cancer, and depression are studied with sufficient female enrollment to support robust sex-disaggregated analyses (4, 5). Third, it means moving from a compliance mindset (simply counting women) to a scientific one: asking sex-specific questions at the outset, powering studies to answer them, and reporting the results clearly and consistently (3, 5). Several practical steps would accelerate progress. Funding agencies can institute targeted calls for applications that explicitly require sex-disaggregated hypotheses and analysis plans, with budget lines for recruitment strategies that reach underrepresented groups. Journals can tighten reporting standards to require sex-specific results in abstracts, main text, and tables, much as Consolidated Standards of Reporting Trials (CONSORT) reporting strengthened the transparency of clinical trials. Data repositories can require that deidentified individual participant data include sex and pregnancy status where applicable, enabling secondary analyses that probe heterogeneity of treatment effects. Measurement practices also need attention. Diagnostic criteria and risk scores should be validated for women, not merely ported from male-dominated cohorts. In cardiovascular medicine, for example, sex-specific troponin thresholds and symptom profiles can improve detection, yet adoption remains uneven (6). In autoimmune disease, integrating patient-reported symptoms with biomarkers could shorten the time to a correct diagnosis and reduce psychosomatic mislabeling (7, 8). Quality improvement collaboratives should routinely audit sex-disaggregated performance for key conditions across emergency, inpatient, and outpatient settings. Finally, diversity in the scientific workforce matters for the questions we ask and the tools we build. Teams that include more women and investigators from historically underrepresented groups are likelier to notice gaps and challenge defaults that others accept as neutral. Similarly, trial networks that partner with community practices, not just academic medical centers, are better positioned to recruit women across age, race, pregnancy status, and comorbidity profiles. Precision medicine cannot be precise if it reflects only a narrow slice of humanity. The case for action is economic as well as scientific. Sex is a powerful axis of biological and social variation. Ignoring it distorts estimates of benefit and harm, leading to missed diagnoses, ineffective treatments, and widening inequities. By investing in rigorous, sex-aware research and embedding sex-disaggregated analysis into design, reporting, and practice, we can close long-standing gaps that limit the reach of precision medicine. The path forward is clear: treat sex differences as an intrinsic part of scientific rigor, fund the questions that women’s health demands, and hold ourselves accountable for results that translate into longer, healthier lives. Female enrollment in US clinical trials versus disease burden, with key policy milestones and NIH funding context. Enrollment data from Sosinsky et al. (5); NIH funding data from NASEM (4); policy timeline from Clayton and Collins (3) and references therein. Credit: H. Al Ibrahim, Adapted by Austin Fisher/Science Advances.